EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection

Raphaël Etiève, Margaux Van Wynsberghe iD, Steven Grangé, Charlotte Laurent, Mathilde Lemoine, Sophie Candon, Dominique Bertrand, Tristan de Nattes iD

Clinical Kidney Journal · 12.12.2025 · 18 (Supplement_2) · ii55-ii64

DOI: 10.1093/ckj/sfaf283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 11.09.2025. Verfasst von Raphaël Etiève und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, CHU Rouen, Rouen, France. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-mediated rejection (AMR) remains a challenge in kidney transplantation, responsible for ≈20% of allograft loss. Given the limited efficiency of conventional therapies, there has been growing interest in new strategies targeting plasma cells. These include anti-CD38 monoclonal antibodies such as daratumumab, felzartamab and isatuximab. These agents, originally developed for haematologic malignancies, offer a novel strategy to target antibody secreting cells and natural killer cells, with the potential to reduce donor-specific antibodies and microvascular inflammation. Emerging clinical data suggest promising efficacy with an acceptable safety profile, sparking growing interest in their use within the transplant community. However, these effects appear transient, with a high interindividual variability, likely influenced by the heterogeneity of B cell populations after establishment of an allo-immune response. Of note, these therapeutics also affect B and T regulatory cells, raising important questions about immune balance with the risk of T cell–mediated rejection. This review synthesizes the current understanding of AMR, presents the Banff 2022 diagnostic frameworks updates and critically appraises the exciting potential and limitations of anti-CD38 therapies in AMR. As the transplant community shifts toward precision immunotherapy, anti-CD38 agents may help reshape future treatment paradigms in kidney transplantation—provided their use is guided by mechanistic insights and rigorous clinical evaluation.

Schlagwörter

Stichwörter der Autor:innen

anti-CD38 therapiesantibody-mediated rejectionantibody-secreting cellsmemory B cellsplasma cells

Autor:innen und Institutionen

  • Nephrology Department, CHU Rouen, Rouen, France.
  • Immunology Department, U1234, Univ Rouen Normandy, CIC-CRB 1404, CHU Rouen, Rouen, France.
  • Nephrology Department, U1234, Univ Rouen Normandy, CIC-CRB 1404, CHU Rouen, Rouen, France.

ORCID-Profile: Margaux Van Wynsberghe, Tristan de Nattes

Zitieren

APA

Etiève, R., Van Wynsberghe, M., Grangé, S., Laurent, C., Lemoine, M., Candon, S., Bertrand, D., & de Nattes, T. (2025). One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection. Clinical Kidney Journal, 18(Supplement_2), ii55-ii64. https://doi.org/10.1093/ckj/sfaf283

Vancouver

Etiève R, Van Wynsberghe M, Grangé S, Laurent C, Lemoine M, Candon S, et al. One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection. Clinical Kidney Journal. 2025;18(Supplement_2):ii55-ii64. doi:10.1093/ckj/sfaf283

BibTeX
@article{Etive2025,
  author = {Etiève, Raphaël and Van Wynsberghe, Margaux and Grangé, Steven and Laurent, Charlotte and Lemoine, Mathilde and Candon, Sophie and Bertrand, Dominique and de Nattes, Tristan},
  title = {One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection},
  journal = {Clinical Kidney Journal},
  year = {2025},
  volume = {18},
  number = {Supplement_2},
  pages = {ii55--ii64},
  doi = {10.1093/ckj/sfaf283}
}
Kostenlos starten →